Updating results

1069 results

Sort: Relevance | Date

Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)

NICE is unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no

Technology appraisal guidance Published July 2017

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to

Technology appraisal guidance Published November 2019

Cenegermin for treating neurotrophic keratitis (TA532)

Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published August 2018

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published August 2018

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine

Technology appraisal guidance Published August 2018

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults

Technology appraisal guidance Published September 2018

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults

Technology appraisal guidance Published September 2016

Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional

Technology appraisal guidance Published September 2016

Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published August 2016

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..

Technology appraisal guidance Published August 2016

Bosutinib for previously treated chronic myeloid leukaemia (TA401)

Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults

Technology appraisal guidance Published August 2016

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

Technology appraisal guidance Published January 2004 Last updated November 2013

Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

Technology appraisal guidance Published November 2003 Last updated July 2011

Guidance on the use of coronary artery stents (TA71)

Evidence-based recommendations on coronary artery stents for treating coronary artery disease (CAD)

Technology appraisal guidance Published October 2003 Last updated July 2008

Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)

Technology appraisal guidance Published October 2003 Last updated January 2016

Guidance on the use of liquid-based cytology for cervical screening (TA69)

Evidence-based recommendations on liquid-based cytology (LBC) for cervical screening

Technology appraisal guidance Published October 2003

Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

Technology appraisal guidance Published August 2003

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Technology appraisal guidance Published March 2017

Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)

NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…

Technology appraisal guidance Published August 2015

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..

Technology appraisal guidance Published October 2015

Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)

NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…

Technology appraisal guidance Published July 2015

Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...

Technology appraisal guidance Published September 2015

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Technology appraisal guidance Published October 2019

Telbivudine for the treatment of chronic hepatitis B (TA154)

Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Entecavir for the treatment of chronic hepatitis B (TA153)

Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

Evidence-based recommendations on cetuximab (Erbitux) for the treatment of locally advanced squamous cell cancer of the head and neck

Technology appraisal guidance Published June 2008

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (TA137)

Evidence-based recommendations on rituximab (MabThera) for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Technology appraisal guidance Published February 2008

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults

Technology appraisal guidance Published January 2012

Mifamurtide for the treatment of osteosarcoma (TA235)

Evidence-based recommendations on mifamurtide (Mepact) for treatment of osteosarcoma (bone cancer)

Technology appraisal guidance Published October 2011

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C

Technology appraisal guidance Published February 2011

Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)

Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults

Technology appraisal guidance Published December 2018

Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

Evidence-based recommendations on arsenic trioxide (Trisenox)for treating acute promyelocytic leukaemia (APML) in adults

Technology appraisal guidance Published June 2018

Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published February 2018

Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2018

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

Technology appraisal guidance Published September 2016

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

Technology appraisal guidance Published October 2019

Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy

Technology appraisal guidance Published March 2015

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

Technology appraisal guidance Published July 2015

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism

Technology appraisal guidance Published August 2015

Naloxegol for treating opioid‑induced constipation (TA345)

Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation that has had inadequate response to laxatives

Technology appraisal guidance Published July 2015

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Technology appraisal guidance Published March 2014

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance Published July 2014

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)

Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)

Technology appraisal guidance Published November 2014